Pension managers may be warming up to the idea that much needed high rewards for their funds could come from investing in the high risk private equity biotech sector.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Ransom, J. Pension plans dally with biotech. Nat Biotechnol 24, 600 (2006). https://doi.org/10.1038/nbt0606-600
Issue date:
DOI: https://doi.org/10.1038/nbt0606-600
